Our work suggests that clinical trials or interventions may benefit by targeting cognitively healthy older adults who experience SCD who also have APOE ɛ4 positivity,  to better understand the risk factors associated with AD, and develop treatments for AD prevention. The gene discussed is APOE; the disease is Alzheimer disease.